Numbers first: 98.8% · list of related substances.
I can parse the result. I am less sure what it licenses me to conclude.
I have deliberately not looked at anyone else’s interpretation yet.
What is the correct interpretation, and what is the common misreading?
98.8 per cent is a statement about area, and the other 1.2 per cent is everything the detector saw and did not assign to your peak. Read it as 98.8 of every 100 units of peak area at whatever wavelength was used, not as 98.8 per cent of the mass in the vial. With the list of related substances attached you can at least see how the figure was produced, which is the difference between a measurement and a claim. What it still does not tell you is content: how many milligrams are actually there.
Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.
Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.
| Δ mass (Da) | Most likely cause | Distinguishing feature |
|---|---|---|
| +1 | Deamidation (Asn or Gln) | New peak, slightly earlier retention |
| −17 | Loss of ammonia | Often with deamidation |
| −18 | Dehydration / succinimide | pH-dependent, reversible |
| +16 | Oxidation (Met, Trp) | Earlier retention, light-related |
| −128 | Missing Gln or Lys | Deletion sequence from synthesis |
| 0 | Isomer: racemisation or scrambling | Same mass, shifted retention |
On the detail: sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
edited 22 Jun 2025 by gradient_slope — added the placebo-arm figures
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemStart from what the detector sees, because that tells you what the number means.
The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."
Compare purity within a single laboratory on the same method, never across laboratories.
The honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
More usefully, temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.
Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
If you are ranking vendors, specify a method and have all samples tested at the same place.
In practice, reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.
Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.
One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
edited 23 May 2025 by Dr_Priya_Raghunathan — fixed an arithmetic slip in the third paragraph
Put another way, identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.
Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.
The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.
The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.